NASDAQ:CPIX
Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc.'s revenue grew 17.6% in fiscal 2025 to $44.5M while operating margin rose to −6.3%. Free cash flow was $4.8M, 10.9% of revenue, and the diluted share count rose 5.6%.Summary generated from Cumberland Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$44.5M
Revenue growth+17.6%
Revenue, 5-yr CAGR+3.5%
Gross margin85.0%
Operating margin−6.3%
Net margin−6.4%
ROICn/a
Return on equity−11.9%
Debt / equityn/a
Free cash flow$4.8M
FCF margin10.9%
Share count change+5.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 36 | 42 | 40 | 38 | 45 |
| Operating income | −8 | −6 | −10 | −6 | −3 |
| Net income | −4 | −6 | −6 | −6 | −3 |
| Free cash flow | 6 | 8 | 6 | −1 | 5 |
Recent filings
- 8-K/AAmended results of a shareholder vote
Sep 11, 2026 - 8-KRegulation FD disclosure
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KOther events
Jul 13, 2026 - 8-KEntry into a material agreement
Jul 1, 2026 - 8-KResults of a shareholder vote
Jun 25, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 8, 2026